Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $2.950.00 (0.00%)
Stock chart for: AXSM.O.  Currently trading at $2.95 with a 52 week high of $6.45 and a 52 week low of $2.75.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial

January 9, 2018COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone resorption confirms potent pharmacologic activity Company to host conference call today at 8:00 AM Eastern NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central n... 

Axsome Therapeutics to Present at Biotech Showcase 2018

December 19, 2017NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at Biotech Showcase 2018 on January 9th, 2018 at 9:30 AM Pacific Time. The conference will be held at the Hilton San Francisco Union Square in San Francisco, CA. A liv... 

Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation

December 14, 2017Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the first quarter of 2018 NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, entered into a research collaboration with Duke Universi...